Pharmacodynamic Activities of Ciprofloxacin and Sparfloxacin in a Murine Pneumococcal Pneumonia Model: Relevance for Drug Efficacy

  1. Jean-Pierre Bédos1,
  2. Esther Azoulay-Dupuis2,
  3. Pierre Moine4,
  4. Martine Muffat-Joly2,
  5. Benoit Veber2,
  6. Jean-Jacques Pocidalo1,2 and
  7. Eric Vallée3
  1. 1Clinique de Réanimation des Maladies Infectieuses, Hôpital Bichat-Claude Bernard, Paris, France (J-P.B.), 2Institut National de la Santé et de la Recherche Médicale U13, Hôpital Bichat-Claude Bernard, Paris, France (E. A-D., M. M-J., B.V., J-J. P.), 3Laboratoire de Biologie, Centre Hospitalier Emile-Roux, Eaubonne, France (E.V.) and 4Département d’Anesthésie-Réanimation Chirurgicale, Centre Hospitalier de Bicêtre, Le Kremlin Bicêtre, France (P.M.)
     
    Next Section

    Abstract

    We looked for associations between pharmacokinetic (Pk) and pharmacodynamic (Pd) parameters of ciprofloxacin (CPFX) and sparfloxacin (SPFX) and the in vivo efficacy of these antimicrobials in an immunocompetent mouse model of severeStreptococcus pneumoniae pneumonia. Bacterial killing curves recorded in the lungs during the 24 h after single subcutaneous injections of the fluoroquinolones (FQs) in doses ranging from 6.25 to 200 mg/kg were compared with mean Pk/Pd parameters in the serum of the same mice. The impact of the dosing interval on the antimicrobial dose response was evaluated based on the survival of mice treated for 3 days with CPFX (25–200 mg/kg) or SPFX (6.25–50 mg/kg) administered at various intervals from 3 to 24 h. Bacterial killing curves showed that the maximal bacterial decrease achieved in the lungs was correlated, similarly for both FQs, with the area under the curve (AUC) above the minimal inhibitory concentration (MIC) (overall correlation: r = 0.968, P < 10−4). CPX attained higher maximal bactericidal effect values, a steeper killing slope and a shorter time to maximal bactericidal effect in comparison with SPX for the highest doses tested. The lower MIC of SPFX compared with CPFX (0.25 vs. 0.75 μg/ml) and its higher AUC/dose ratio (resulting from a lower serum peak but a longer half-life) translated into a greater area under the bactericidal curve. In the dose fractionation experiments, the Pk/Pd parameter most closely correlated with the survival rate for both FQs was the daily AUC/MIC ratio (r = 0.976, P < 10−4). When the AUC/MIC ratio was greater than 160, the probability of a clinical cure was 100%, independently of the dosage schedule.

    The therapeutic potential of antibacterial compounds is primarily determined by their in vitro activity and their in vivo pharmacokinetics. Among respiratory pathogens,Haemophilus influenzae and Moraxella catarrhalisare inhibited by all FQs in concentrations of less than 0.25 μg/ml (Hooper and Wolfson, 1991). FQs have large apparent volumes of distribution, and as a result, their peak serum concentrations are generally no higher than 6 mg/l (Neuman, 1988). On the other hand, the good diffusion of FQs into body tissues, which includes penetration into the extravascular and intracellular compartments (Nix et al., 1991), may be valuable in the treatment of bacterial pneumonia (pulmonary tissue-to-serum ratio >2) (Davies and Maesen, 1986). Based on their activity against Streptococcus pneumoniae, the organism responsible for about 50% of bacteriologically documented community-acquired pneumonias (Moineet al., 1994), FQs can be classified into three groups (Piddock, 1994): (1) compounds whose in vitro MICs are far greater than concentrations achievable in humans (8–16 μg/ml) and therefore inconsistent with therapeutic efficacy, e.g.,pefloxacin, enoxacin, fleroxacin and lomefloxacin; (2) compounds with lower MICs (1– 4 μg/ml) that, however, remain close enough to achievable serum peak levels to carry a risk of therapeutic failure (Perrez-Tallero et al., 1990; Lee et al., 1991) and of selection of resistant mutants (Lafredo et al., 1993;Bernard et al., 1994) when these compounds are used in standard regimens, e.g., ciprofloxacin and ofloxacin; (3) newer compounds, most notably sparfloxacin, whose in vitroactivity is improved (MICs, 0.125–0.5 μg/ml), such as sparfloxacin, trovafloxacin, clinafloxacin, grepafloxacin, DU-6895a and BAY 12–8039 (Stein, 1996). However, routine MIC determination provides information only on in vitro susceptibility of bacteria. We previously have showed the greater efficacy of sparfloxacin compared with ciprofloxacin and ofloxacin, in relation to its prolonged elimination half-life, in experimental mouse pneumonia models (Azoulay-Dupuiset al., 1992).

    The specific relationships that link pharmacokinetic parameters (e.g., peak serum concentration, AUC,T1/2) to parameters measuring pharmacodynamic interactions between the antimicrobial and the bacteria (i.e., the MIC) can be used to define Pk/Pd surrogate markers for bacterial killing or clinical cure endpoints (Hyattet al., 1995). These Pk/Pd parameters depend on the antimicrobial class. A recently published abstract by Andes et al. (1995) reported that maximum efficacy for the β-lactam amoxicillin against S. pneumoniae was achieved when serum levels exceeded the MIC of the strain during 40 to 50% of the dosing interval. In experimental animal pneumonia models, evidence has been found that the AUC/MIC ratio and the peak/MIC ratio may be the most useful Pk/Pd surrogates for bacterial killing of Klebsiella pneumoniae or Pseudomonas aeruginosa by FQs; this has been demonstrated, in particular, for CPFX in a model of neutropenic animals (Schentag et al., 1993).

    We used a mouse model of severe pneumococcal pneumonia both to determine the Pk/Pd parameters that best reflect pulmonary killing curves and clinical cure endpoints and to evaluate the impact of dosing intervals on treatment efficacy during administration of two FQs, CPFX and SPFX. We chose these two marketed drugs because they belong to the same quinolone class but exhibit different profiles: CPFX, whose efficacy may be amenable to improvement and whose short half-life, unchanged in infected animals (Vallée et al., 1992), allows use of divided doses to avoid potential risks of accumulation, and SPFX, which has the lowest MICs against S. pneumoniaeand a long half-life, in particular in infected animals (Azoulay-Dupuiset al., 1992). (This work was presented in part at the 33rd International Conference on Antimicrobial Agents and Chemotherapy, New Orleans, October 17–20, 1993, abstract 83).

    Previous SectionNext Section

    Materials and Methods

    Animals.

    Female C57Bl/6 mice aged 6 to 7 weeks and weighing 18 to 20 g were obtained from Iffa-Credo Laboratories (L’Arbesle, France) and housed in our laboratory for 1 week before the experiment.

    Bacterial strain.

    S. pneumoniae (Sp) strain P4241, a virulent serotype 3 originally isolated from blood and kindly provided by the Centre de Référence du Pneumocoque (Dr. P. Geslin, Créteil, France), was used throughout the study. The isolate was stored at −70°C in brain-heart infusion broth (Bio-Mérieux, Lyon, France) supplemented with 5% filtered horse serum (Diagnostic Pasteur, Ville D’Avray, France) and nutrient broth (10% glycerol, 4% sorbitol; Difco Laboratories, Paris).

    Antibiotics.

    CPFX was provided by Bayer Laboratories (Wuppertal, Germany) and SPFX by Rhône-Poulenc-Rorer (Vitry-sur-Seine, France). An aqueous solution of the hydrochloride salt of CPFX was used for subcutaneous injections to mice. SPFX base was prepared for in vivo experiments by homogenizing the powder in a standard diluent containing carboxymethylcellulose (70 cP) in a concentration of 2 g % in isotonic saline solution (0.09%).

    In vitro susceptibility tests.

    MICs and MBCs for the test strain were determined with microtiter broth dilution techniques with Mueller-Hinton infusion broth (Difco, Detroit, MI) as the test medium and final inocula ranging from 5 × 105 to 107 CFU/well. The MIC was defined as the lowest antimicrobial concentration preventing visible growth after aerobic incubation for 18h at 37°C. The MBC was determined by plating 0.01-ml samples from wells with no visible growth onto horse blood agar (Bio-Mérieux, Lyon, France), incubating the plates overnight at 37°C under aerobic conditions and recording the lowest antimicrobial concentration that killed >99.9% of the original inoculum.

    Experimental pneumonia model.

    Pneumococcal pneumonia was induced in mice as described in detail elsewhere (Azoulay-Dupuiset al., 1991a). Mice anesthetized by intraperitoneal injection of sodium pentobarbital were inoculated endotracheallyvia the mouth with about 105 log-phase CFU of the Sp test strain. The mice developed subacute pneumonia and died within 7 days, with the peak mortality rate occurring on the fifth day after inoculation. Bacteremia developed within 6 h in half the animals and within 24 h in all animals, and lung bacterial counts increased progressively. Bacterial counts were greater than 108 CFU/lung and 106 CFU/ml of blood at the time of death.

    In vivo bacterial killing kinetics.

    The time course of bactericidal activity was recorded in the lungs during the 24-h period after single subcutaneous injections of CPFX (25, 50, 100 and 200 mg/kg) or SPFX (6.25, 12.5, 25 or 50 mg/kg). A group of untreated control mice also was studied. The FQs were administered 48 h after inoculation with S. pneumoniae, at which time there was histological evidence of advanced experimental pneumonia (Azoulay-Dupuis et al., 1991a). Mice were sacrificed by CO2 asphyxiation. The lungs and blood of mice (n = 3) were collected 1, 3, 6, 9, 12 and 24 h after drug administration. Blood was collected by intracardiac puncture and was used for qualitative cultures (brain-heart infusion broth, Difco). Lungs were harvested from exsanguinated mice, washed and homogenized in 1 ml of sterile saline solution (Ultra-Turrax T25, Ika-Labortechnik, Staufen i. Br., Germany). Viable bacteria were counted in whole-lung homogenates by plating 0.1 ml of serial 10-fold dilutions of samples onto Columbia agar with 5% sheep blood and incubating the agar aerobically for 24 h at 37°C. Results are expressed as log10 CFU/lungs (limit of detection: 1 log CFU). Emax is the maximal bactericidal effect observed (maximal log CFU reduction) with each tested dose of antimicrobial relative to untreated control mice. The %AUBC designates the area under the bactericidal curve observed during the 24-h period after drug administration, relative to that under the growth curve of untreated control animals.

    Therapeutic trials.

    Treatment was initiated 48 h after inoculation, as mentioned above. Antibiotics were administered subcutaneously for 3 days as repeated doses every 24, 12, 8, 6 or 3 h. Fifteen animals per treatment group were used, and groups were randomized to treatment conditions. All animals in each experiment were infected simultaneously. Experiments were repeated at least twice. Cumulative survival rates were recorded daily for 10 days in each treatment group. Results are expressed as per cent survival rates 7 days after the end of therapy (no deaths occurred after this time interval).

    Pharmacokinetic studies.

    The antimicrobial concentrations in serum were determined in infected mice. CPFX and SPFX were administered subcutaneously 48 h after inoculation with S. pneumoniae. Doses used were as follows: 25, 50, 75, 100, 150 and 200 mg/kg of CPFX and 6.25, 12.5, 25 and 50 mg/kg of SPFX. The mice were sacrificed with diethylether, and the blood from groups of three mice were collected 0.5, 1, 3, 5, 7, 9, 12 and 24 h after drug administration, as described previously (Vallée et al., 1992). Drug concentrations were determined by the agar well diffusion method with Escherichia coli ATCC 39118 as the indicator organism and Antibio-Medium 2 (Difco) as the test medium. Standard solutions of CPFX and SPFX in phosphate buffer, pH 6.8, were prepared for detection of the active free fraction of the drugs in the specimens. Concentrations were determined by averaging diameters from three replicate plates and comparing the results to a standard curve. Results were expressed as micrograms per milliliter of serum. The standard curves were linear from 0.06 to 32 μg/ml, and the lower limit of sensitivity was 0.06 μg/ml for both CPFX and SPFX. The coefficient of between- and within-day variation for replicates (n = 5) was ≤5% for both FQ assays. Concentration-time data were modeled, and pharmacokinetic parameters (peak level, T1/2β and AUC) were calculated by nonlinear least-squares regression analysis (nonlinear Apis software, Mips, Marseille, France). Multiple models were evaluated. Best fit of experimental points was obtained with a one-compartment model with zero-order absorption and first-order elimination. Optimization was accomplished by use of the maximum likehood estimation criterion.

    Statistical analysis.

    The observers involved in data collection and analysis were not completely blind to treatment conditions. However, the methodology used for sample identification prevented subjective bias in the experiments. On the other hand, doses and animals were randomized to treatment conditions. Data are expressed as mean ± S.D. Means were compared between groups by one-way or two-way (drug/dose) variance analysis. Correlations between parameters were sought by use of the linear regression coefficient r. Constant terms of the regression lines computed for the two FQs were compared when appropriate. To define the relationship between survival rate and Pk/Pd indexes at the steady state, the regression method was applied to the linear portion of the theoretically sigmoid curve (i.e., excluding 0 and 100% survival data). P values of .05 or less were considered significant. All statistical analyses were conducted with version 4.5 of Statview, Abacus Concepts, Inc., Berkeley, CA.

    Previous SectionNext Section

    Results

    MIC and MBC determinations.

    Against the challenge organism, MICs were 0.75 μg/ml for CPFX and 0.25 μg/ml for SPFX. MBC values were twice the MICs. Inoculum size, which ranged from 5 × 105 to 107 CFU/ml did not affect these values.

    Pharmacokinetics in mouse serum.

    Single-dose pharmacokinetics of CPFX and SPFX administered at various doses were modeled from data from individual animals. Profiles were best described by a one-compartment model with monoexponential elimination. Parameter estimates and profiles were used to calculate the AUC above the MIC (AUC>MIC) and the time spent with serum concentrations greater than the MIC of the challenge strain (ΔtMIC). The mean data for various doses of CPFX and SPFX are reported in table1. For both FQs significant linear correlations were found between peak level,T1/2 or AUC and doses, with P values <10−4 in all cases (peak levelvs. dose: r = 0.880 and 0.916;T1/2vs. dose: 0.851 and 0.932; AUC vs. dose: r = 0.865 and 0.956 for CPFX and SPFX, respectively). At similar doses, i.e., 25 and 50 mg/kg, peak levels were lower for SPFX than CPFX (P = .020), but half-lives were longer (P < 10−4) and AUCs larger (P = .0016). This, added to lower MIC for SPFX, resulted in significantly higher values of pharmacodynamic parameters and greater potency of SPFX than CPFX, i.e., peak/MIC ratio (P < 10−4), AUC/MIC ratio (P < 10−4), AUC>MIC (P = .0005) and ΔtMIC (P < 10−4).

    View this table:
    Table 1

    Pharmacokinetic and pharmacodynamic parameters achieved for CPFX and SPFX in the serum of infected mice after single s.c. injections administered 48 h after infection1-a

    In vivo bacterial killing.

    Bacterial killing curves in lung for the various doses of CPFX and SPFX are shown in figure 1, and killing constants calculated from experimental data are given in table2. At similar doses (i.e., 25 and 50 mg/kg) bactericidal effect was greater for SPFX than for CPFX, which indicated a difference in potency (P = .0074). Killing rate was not dose-dependent and was significantly slower with SPFX than with CPFX (0.34 ± 0.05 vs. 0.56 ± 0.06 log CFU/h, P = .0009), but the bactericidal effect of SPFX lasted much longer.

    Figure 1
    View larger version:
    Figure 1

    (a) Bacterial clearance from the lungs after single s.c. injections of various doses of CPFX (mg/kg) at various times after infection. (b) Bacterial clearance from the lungs after single s.c. injections of various doses of SPFX (mg/kg) at various times after infection.

    View this table:
    Table 2

    Variables of bacterial killing for S. pneumoniae P4241 in the lungs of mice after single s.c. injections of CPFX and SPFX

    For both CPFX and SPFX significant correlations were found between experimental Emax values and log expression of estimates of Pk/Pd parameters in serum (log peak/MIC ratio, log AUC/MIC ratio, log AUC>MIC and log ΔtMIC) (fig.2). The parameter that demonstrated the closest correlation with the Emax values for both FQs was AUC>MIC (r = 0.968, P < 10−4), but the correlation with peak/MIC ratio was also strong (r = 0.934, P = .0007).

    Figure 2
    View larger version:
    Figure 2

    Relationships between various Pk/Pd parameters andEmax for CPFX and SPFX, derived from pulmonary bacterial killing curves after single injections in ourS. pneumoniae pneumonia model.

    The %AUBC, which takes into account both killing kinetics and bactericidal effect duration, was correlated significantly with all the above-mentioned Pk/Pd parameters (fig.3). The closest correlation evidenced was that with log ΔtMIC (r = 0.991, P < 10−4), followed by that with log AUC/MIC (r = 0.976, P < 10−4). Regression lines for the two FQs cannot be superimposed only for %AUBC versus log AUC>MIC, despite the fact no significant difference could be found.

    Figure 3
    View larger version:
    Figure 3

    Relationships between various Pk/Pd parameters and %AUBC for CPFX and SPFX, derived from pulmonary bacterial killing curves after single injections in our S. pneumoniaepneumonia model.

    Therapeutic trials.

    The goal of the therapeutic trials was to evaluate the impact of dose fractionation on treatment efficacy. We selected the minimal daily dosage that provided a 75 to 80% survival rate in infected animals when administered once daily for 3 days. This daily dosage was then fractionated into two, four or eight doses (given every 12, 6 or 3 h, respectively) (table3). With CPFX (200 mg/kg/day), survival rate was significantly higher in the once-daily dosing group than the other three regimens which gave similar outcome (75 ± 9%vs. 29 ± 14%, P = .0004). With SPFX, survival rate was not modified significantly by fractionation of the daily dosage (50 mg/kg). The eight-time daily schedule was not used with SPFX because it resulted in major drug accumulation from dose to dose.

    View this table:
    Table 3

    Results of dose fractionation experiments

    Evaluation of associated Pk/Pd parameters (steady state) showed that survival was unrelated to ΔtMIC. With CPFX, survival was longest in the animals with the shortest ΔtMIC. However, the other Pk/Pd parameters, higher with the once-daily dosage than with the three fractionated schedules, are consistent with better survival rate.

    More accurate examination of the quantitative relationship between Pk/Pd parameters and therapeutic efficacy observed using a broader range of daily doses and dosing schedules is shown on figure4. Close correlations with the survival rate were found for only two parameters, both of which depended on the AUC, namely AUC/MIC ratio and AUC>MIC. Despite minor differences between the two regression lines representing the percent survival rateversus AUC/MIC ratio, estimates of breakpoint for 100% survival for CPFX and SPFX are very close (95% CI: 152–163 and 161–173, respectively). The overall regression line computed with data for both FQs (i.e., % survival = 0.87 × [AUC/MIC ratio] − 41.7, n = 20, r = 0.976, P < 10−4) permits to estimate a common breakpoint of AUC/MIC ratio at a mean value of 164 (95% CI: 159–170). Survival rate was also closely correlated with AUC>MIC, but in this case, regression lines representative of the two FQs are significantly different and lead to different 100% survival breakpoint estimates (95%CI: 91–104 and 32–45 for CPFX and SPFX, respectively).

    Figure 4
    View larger version:
    Figure 4

    Relationships between various Pk/Pd parameters and survival rate for CPFX and SPFX, derived from dose fractionation experiments in our S. pneumoniae pneumonia model.

    No FQ-resistant strains were found in the lungs of dead animals treated with the ineffective regimens (e.g., CPFX 100 mg/kg twice daily or 50 mg/kg three times a day, and SPFX 6.25 mg/kg three times a day or 12.5 mg/kg twice daily).

    Previous SectionNext Section

    Discussion

    S. pneumoniae is the most common cause of severe, community-acquired, bacterial pneumonia, of which many cases are fatal (Moine et al., 1995). The increasing emergence throughout the world of S. pneumoniae strains with resistance to β-lactams and other antimicrobials (Baquero, 1995) is raising new therapeutic challenges. Demonstration of antipneumococcal efficacy of new classes of antimicrobials broadens the therapeutic armamentarium available for S. pneumoniae pneumonia. FQs are not only active on intracellular organisms responsible for community-acquired pneumonia (Thyset al., 1991) but also exhibit similarin vitro activity on S. pneumoniae strains with and without susceptibility to penicillin (Canton et al., 1992). Rational selection of an antimicrobial and of its administration route for the treatment of a focus of bacterial infection requires knowledge of the specific relationships that link the pharmacokinetic parameters of the drug to parameters reflecting pharmacodynamic interactions between the drug and the bacterium (e.g., the MIC) (Dudley, 1991; Nix and Schentag, 1988; Hyatt et al., 1995). Studies have found that the efficacy of β-lactams is correlated with the time spent with serum antimicrobial levels above the MIC for the causative organisms, and that the efficacy of aminoglycosides is correlated with the peak/MIC ratio or the AUC/MIC ratio (Vogelman et al., 1988; Craig et al., 1991). In our experimental study, we used two in vivopharmacodynamic endpoints, intrapulmonary bacterial killing after single antibiotic injections and survival after therapy with fractionated doses. We also used two parameters for evaluating bacterial killing, Emax (the maximal bactericidal effect) and %AUBC (the total bactericidal effect throughout time). In our model, intrapulmonary bacterial killing by CPFX or SPFX depended on the concentration of the antimicrobial, in keeping with previous studies (Vallée et al., 1991). All Pk/Pd study parameters were correlated strongly withEmax, based on their covariance (Schentaget al., 1993; Peloquin et al., 1989), but the strongest correlation was seen with AUC>MIC, a parameter that reflects both the concentration of the drug and the time spent with a concentration greater than the MIC for the causative pathogen. AUC>MIC represents the amount of drug above the inhibition threshold and depends both on the peak serum level and on the half-life of the drug. In our experiments, peak/MIC seems to have a greater contribution to achievement of the Emax than the half-life. For a given peak/MIC value, Emax values for CPFX and SPFX were similar; Emax was greater than 2 log10 CFU/ml of lung homogenate when the peak/MIC ratio was >7. On the other hand, CPFX was characterized by a shorter time to Emax and a steeper killing slope after a single injection. These differences are probably ascribable to the more favorable AUC>MIC value of CPFX. The %AUBC incorporates a time component and therefore the possibility of bacterial regrowth. The close correlation between %AUBC and ΔtMIC therefore was expected. For a given peak/MIC value, %AUBC was consistently greater for SPFX, whose half-life is longer than that of CPFX. The strong influence of ΔtMIC was consistent with the absence of any postantibiotic effect in our in vivo model; studies done in vitro found a modest postantibiotic effect that ranged from 2 to 6 h in duration according to the bacterial species (Chin and Neu, 1987). It has been reported that a peak/MIC value greater than 8 prevented selection of resistant P. aeruginosa strains (Blaser et al., 1987; Leggettet al., 1991; Drusano et al., 1993). Because resistance rarely emerges in vivo after a single injection, we looked for resistant strains in animals that failed to respond to various multiple-dose therapeutic regimens. None of these animals harbored any resistant strains.

    A few animal studies have focused on the Pk/Pd parameters predictive of clinical cure in S. pneumoniae pulmonary infections (Azoulay-Dupuis et al., 1991b, 1992). With a dose fractionation approach, which was the only means to identify differences among variables, we found that the AUC/MIC was the best predictor of survival, and that an AUC/MIC of 160 or more was associated with a 100% clinical cure rate independently from the dosage schedule. In contrast, AUC/MIC breakpoints probably vary across experimental models. Lower AUC/MIC values have provided similar efficacy in models of less severe S. pneumoniae infection with SPFX and levofloxacin (Vesga and Craig, 1995; Vesga et al., 1995). Also with the dose fractionation approach, Drusanoet al. (1993) found that the significance of AUC/MIC in a neutropenic rat model of Pseudomonas sepsis varied with the peak/MIC ratio; if it is high (10–20), peak/MIC ratio was linked to survivorship, but at lower doses, producing peak/MIC ratios lower than 10, the AUC/MIC was linked closely to outcome. In a study of a mouse protection model, Sullivan et al. (1993) found that 100% protection by CPFX was achieved when the peak/MIC ratio reached 10.6. From an analysis of data from several clinical trials of patients with nosocomial pneumonia caused by Gram-negative bacilli, Schentag and colleagues determined that an AUC/MIC of 125 was required to achieve a clinical cure and that AUC/MIC values in the 250 to 500 range were associated with increased in vivo bacterial killing (Forrestet al., 1993; Hyatt et al., 1994). In our study of an S. pneumoniae model, 100% clinical cure was achieved with an AUC/MIC value of 160, which suggests that Pk/Pd parameters of FQ activity in severe pneumonia may be quite similar for Gram-negative bacilli and S. pneumoniae. The MIC of the bacterium to be eradicated should be confronted with kinetic data. For instance, when using CPFX in a high dose of 400 mg every 8 h intravenously, an AUC/MIC value in excess of 125 (the lowest effective value) was achieved only when the MIC of the causative organism (S. pneumoniae, Staphylococcus aureus, P. aeruginosa) was less than 0.5 mg/l (Hyatt et al., 1994). Concerning interspecies differences, comparisons of in vitro killing curves for CPFX at different concentrations (1.55–25 mg/l), demonstrated a concentration-effect relationship not only for P. aeruginosa but also for S. pneumoniae and S. aureus (all these organisms have equivalent MICs of 0.4 mg/l) with only subtle differences in killing rates (Hyatt et al., 1994).

    This experimental approach shows clearly that optimization of FQ therapy for an S. pneumoniae infection requires knowledge of both the MIC of the organism and the serum pharmacokinetic parameters of the drug with the dosing schedule used. Only the relationships between these two types of parameters can provide information on the antipneumococcal potential of a FQ. The Pk/Pd data provided by our study could explain why CPFX therapy is inconsistently effective in severe pneumococcal pneumonia (MIC90 ≥ 2 mg/l, low peak/MIC and AUC/MIC) (Cooper and Lawlor, 1989; Scully, 1993). SPFX has several characteristics suggestive of better antipneumococcal activity, including a lower MIC (MIC 90 = 0.25 mg/l) (Chinet al., 1991) and a longer half-life (20 h), although it also has a low serum peak (1.7 mg/l after 400 mg per os), it has a greater AUC0–24 of about 35 mg·h/l and then an AUC/MIC of 140 (Montay et al., 1994). Owing to these better Pk/Pd parameters, SPFX has been proven effective in pneumococcal pneumonia without criteria for severe disease (Aubier et al., 1996).

    To be sufficiently active against S. pneumoniae and useful for the empirical treatment of community-acquired pneumonia, a FQ would have to exhibit a higher AUC/MIC ratio (i.e., lower MICs and/or higher AUCs via a higher serum peak and/or a longer half-life) and at the same time maintain a satisfactory safety-side effects profile.

    Previous SectionNext Section

    Footnotes

    • Send reprint requests to: J.P. Bédos, Service de Réanimation des Maladies Infectieuses, Hôpital Bichat Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France.

    • 1 Deceased.

    • Abbreviations:
      Sp
      Streptococcus pneumoniae
      FQs
      fluoroquinolones
      SPFX
      sparfloxacin
      CPFX
      ciprofloxacin
      MIC
      minimal inhibitory concentration
      AUC
      area under the curve
      T1/2
      elimination half-life
      ΔtMIC
      duration for which serum drug concentrations exceed the MIC
      AUC/MIC ratio
      AUC relative to the MIC
      AUC>MIC
      AUC above the MIC
      Emax
      maximal bactericidal effect
      AUBC
      area under the bactericidal curve
      CFU
      colony forming units
      Pk
      pharmacokinetic
      Pd
      pharmacodynamic
      CI
      confidence interval
      MBC
      minimal bactericidal concentration
      • Received July 2, 1997.
      • Accepted March 5, 1998.
    Previous Section
     

    References

    1. ↵
      1. Andes D,
      2. Urban A,
      3. Craig WA
      (1995) In-vivo activity of amoxicillin and amoxicillin/clavulanate against penicillin-resistant pneumococci. Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (Annual Meeting of the American Society for Microbiology, San Francisco, CA), A82:16.
    2. ↵
      Aubier M, Lode H, Gialdrani-Grassi G, Huchon G, Hosie J, Regamey C, Segev S, Vester R, Wijnands WJ and Tolstuchow N (1996) Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies. J Antimicrob Chemother 37 (Suppl. A):73–82..
    3. ↵
      1. Azoulay-Dupuis E,
      2. Bedos JP,
      3. Vallee E,
      4. Hardy DJ,
      5. Swanson RN,
      6. Pocidalo JJ
      (1991a) Antipneumococcal activity of ciprofloxacin, ofloxacin and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. J Infect Dis 163:319–324.
      MedlineWeb of Science
    4. ↵
      Azoulay-Dupuis E, Bedos JP, Vallee E and Pocidalo JJ (1991b) Comparative activity of fluorinated quinolones in acute and subacuteS pneumoniae models. J Antimicrob Chemother 28 (Suppl. C):45–53..
    5. ↵
      1. Azoulay-Dupuis E,
      2. Vallee E,
      3. Veber B,
      4. Bedos JP,
      5. Bauchet J,
      6. Pocidalo JJ
      (1992) In-vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multi-resistant strains of Streptococcus pneumoniae in a mouse model of pneumonia. Antimicrob Agents Chemother 36:2698–2703.
      Abstract/FREE Full Text
    6. ↵
      1. Baquero F
      (1995) Pneumococcal resistance to betalactam antbiotics. A global overwiew. Microbiol Drug Res 1:113–120.
    7. ↵
      1. Bernard L,
      2. Nguyen Van J-C,
      3. Mainardi J-L
      (1994) In-vivo selection of Streptococcus pneumoniae resistant to quinolones, including sparfloxacin. Clin Microbiol Infect 1:60–61.
    8. ↵
      1. Blaser J,
      2. Stone BB,
      3. Groner MC,
      4. Zinner SH
      (1987) Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 31:1054–1060.
      Abstract/FREE Full Text
    9. ↵
      1. Canton SM,
      2. Pelman J,
      3. Jimenez MT,
      4. Ramon MS,
      5. Gobernado M
      (1992) In-vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrob Agents Chemother 36:558–565.
      Abstract/FREE Full Text
    10. ↵
      Chin NX and Neu HC (1987) Post antibiotic suppressive effect of ciprofloxacin against gram positive and gram negative bacteria.Am J Med 82 (Suppl. 4A):58–62..
    11. ↵
      1. Chin NX,
      2. Gu JW,
      3. Yu KW,
      4. Zhang YX,
      5. Neu HC
      (1991) In-vitro activity of sparfloxacin. Antimicrob Agents Chemother 35:567–571.
      Abstract/FREE Full Text
    12. ↵
      1. Cooper B,
      2. Lawlor M
      (1989) Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia. Am J Med 87:475.
      MedlineWeb of Science
    13. ↵
      Craig WA, Redington J and Ebert SC (1991) Pharmacodynamics of amikacinin-vitro and in experimental infections. J Antimicrob Chemother 27 (Suppl. C):29–40..
    14. ↵
      1. Davies BL,
      2. Maesen FPB
      (1986) Quinolones in chest infections. J Antimicrob Chemother 18:296–299.
      FREE Full Text
    15. ↵
      1. Drusano GL,
      2. Johnson DE,
      3. Rosen M,
      4. Standiford HC
      (1993) Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 37:483–490.
      Abstract/FREE Full Text
    16. ↵
      Dudley MN (1991) Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am J Med91 (Suppl 6A):45S–50S..
      1. Dudley MN,
      2. Mandler HD,
      3. Gilbert D,
      4. Ericson J,
      5. Mayer KH,
      6. Zinner SH
      (1987) Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Am J Med 82:363–368.
      CrossRefMedlineWeb of Science
    18. ↵
      1. Forrest A,
      2. Nix DE,
      3. Ballow CH,
      4. Goss TF,
      5. Birmingham MC,
      6. Schentag JJ
      (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37:1073–1081.
      Abstract/FREE Full Text
    19. ↵
      1. Hyatt JM,
      2. Nix DE,
      3. Schentag JJ
      (1994) Pharmacokinetics and pharmacodynamics of ciprofloxacin against similar MIC strains of S pneumoniae, S aureus, and P aeruginosa using kill curve methodology. Antimicrob Agents Chemother 38:2730–2737.
      Abstract/FREE Full Text
    20. ↵
      1. Hyatt JM,
      2. Mckinnon PS,
      3. Zimmer GS,
      4. Schentag JJ
      (1995) The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome, Focus on antibacterial agents. Clin Pharmacokinet 28:143–160.
      MedlineWeb of Science
    21. ↵
      1. Hooper DC,
      2. Wolfson JS
      (1991) Fluoroquinolone antimicrobial agents. N Engl J Med 324:384–394.
      MedlineWeb of Science
    22. ↵
      1. Lafredo SC,
      2. Foleno BD,
      3. Fu KP
      (1993) Induction of resistance of Streptococcus pneumoniae to quinolones in vitro. Chemotherapy 39:36–39.
      Medline
    23. ↵
      1. Lee BL,
      2. Padula AM,
      3. Kimbrough RC,
      4. Jones SR,
      5. Chaisson RE,
      6. Mills J,
      7. Sandy MA
      (1991) Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 325:520.
      MedlineWeb of Science
    24. ↵
      Leggett JE, Ebert S, Fantin B and Craig WA (1991) Comparative dose-effect relations at several dosing intervals for β-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis 74 Suppl.:179–84..
    25. ↵
      1. Moine P,
      2. Vercken JB,
      3. Chevret S,
      4. Chastang C,
      5. Gadjos P,
      6. The French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit
      (1994) Severe community-acquired pneumonia. Etiology, epidemiology and prognosis factors. Chest 105:1487–1495.
      Abstract/FREE Full Text
    26. ↵
      1. Moine P,
      2. Vercken JB,
      3. Chevret S,
      4. Gajdos P,
      5. The French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit
      (1995) Severe community-acquired pneumococcal pneumonia. Scand J Infect Dis 27:201–206.
      Medline
    27. ↵
      1. Montay G,
      2. Bruno R,
      3. Vergniol JC,
      4. Ebmeier M,
      5. Le Roux Y,
      6. Guimart C,
      7. Frydman A,
      8. Chassard D,
      9. Thebault JJ
      (1994) Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg. J Clin Pharmacol 34:1071–1076.
      Abstract
    28. ↵
      1. Neuman M
      (1988) Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet 14:96–121.
      Medline
    29. ↵
      1. Nix DE,
      2. Schentag JJ
      (1988) The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics. J Clin Pharmacol 28:169–178.
      Medline
    30. ↵
      1. Nix DE,
      2. Goodwin D,
      3. Peloquin CA,
      4. Rotella DL,
      5. Schentag JJ
      (1991) Antibiotic tissue penetration and its relevance: Models of tissue penetration and their meaning. Antimicob Agents Chemother 35:1947–1952.
      FREE Full Text
    31. ↵
      1. Perrez-Tallero E,
      2. Garcia-Arenzana JM,
      3. Jiminez JA,
      4. Peris A
      (1990) Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. Eur J Clin Microbiol Clin Dis 9:905–906.
      CrossRefMedlineWeb of Science
    32. ↵
      1. Peloquin CA,
      2. Cumbo TJ,
      3. Nix DE,
      4. Sands MF,
      5. Schentag JJ
      (1989) Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Arch Intern Med 149:2269–2273.
      Abstract/FREE Full Text
    33. ↵
      1. Piddock LJV
      (1994) New quinolones and gram-positive bacteria. Antimicrob Agents Chemother 38:163–169.
      FREE Full Text
    34. ↵
      1. Hooper DC,
      2. Wolfson JS
      1. Schentag JJ,
      2. Nix DE,
      3. Forrest A
      (1993) Pharmacodynamics of the fluoroquinolones. in Quinolone Antimicrobial Agents, eds Hooper DC, Wolfson JS (American Society for Microbiology, Washington, DC.) 2nd ed, pp 259–271.
    35. ↵
      1. Wolfson JS,
      2. Hooper DC
      1. Scully BE
      (1993) Therapy of respiratory tract infections with quinolone antimicrobial agent. in Quinolone Antimicrobial Agents, eds Wolfson JS, Hooper DC (American Society for Microbiology, Washington, DC.) 2nd ed, pp 339–362.
    36. ↵
      Stein GE (1996) Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis23 (Suppl 1):S19–S24..
    37. ↵
      1. Sullivan MC,
      2. Cooper BW,
      3. Nightingale CH,
      4. Quintiliani R,
      5. Lawlor MT
      (1993) Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model. Antimicrob Agents Chemother 37:234–239.
      Abstract/FREE Full Text
    38. ↵
      1. Thys JP,
      2. Jacobs F,
      3. Byl B
      (1991) Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 10:304–315.
      CrossRefMedlineWeb of Science
    39. ↵
      Vallee E, Azoulay-Dupuis E, Pocidalo JJ and Bergogne-Berezin E (1991) Pharmacokinetics of four fluoroquinolones in an animal model of infected lung. J Antimicrob Chemother 28 (Suppl. C):39–44..
    40. ↵
      1. Vallee E,
      2. Azoulay-Dupuis E,
      3. Bauchet J,
      4. Pocidalo JJ
      (1992) Kinetic disposition of temafloxacin and ciprofloxacine in a murine model of pneumococcal pneumonia. relevance for drug efficacy. J Pharmacol Exp Ther 262:1203–1208.
      Abstract/FREE Full Text
    41. ↵
      1. Vesga O,
      2. Craig WA
      (1995) Activity of levofloxacin against penicillin-resistant Streptococcus pneumoniae in normal and neutropenic mice. Program and Abstracts of the 36h Interscience Conference on Antimicrobial Agents and Chemotherapy (Annual Meeting of the American Society for Microbiology, New Orleans, LA), A59:12.
    42. ↵
      1. Vesga O,
      2. Conklin R,
      3. Stamstad T,
      4. Craig WA
      (1995) In-vivo pharmacodynamic activity of sparfloxacin against multiple bacterial pathogens. Program and Abstracts of the 36h Interscience Conference on Antimicrobial Agents and Chemotherapy (Annual Meeting of the American Society for Microbiology, New Orleans, LA), A65:13.
    43. ↵
      1. Vogelman B,
      2. Gudmunsson S,
      3. Leggett J,
      4. Turnidge J,
      5. Ebert S,
      6. Craig WA
      (1988) Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 158:831–847.
      MedlineWeb of Science
    « Previous | Next Article »Table of Contents

    This Article

    1. JPET July 1, 1998 vol. 286 no. 1 29-35
    1. AbstractFree
    2. » Full Text
    3. Full Text (PDF)

    Classifications

    Responses

    1. Submit a response
    2. No responses published

    Navigate This Article

    Current Issue

    1. November 2009, 331 (2)
    1. Current Issue
    1. Alert me to new issues of JPET